Bruce G. Allen Investments LLC Has $58,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

Bruce G. Allen Investments LLC boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1,013.6% in the third quarter, Holdings Channel.com reports. The fund owned 245 shares of the medical research company’s stock after buying an additional 223 shares during the quarter. Bruce G. Allen Investments LLC’s holdings in IQVIA were worth $58,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in IQV. Versant Capital Management Inc raised its holdings in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares during the period. Opal Wealth Advisors LLC bought a new stake in IQVIA during the 2nd quarter worth approximately $27,000. Park Place Capital Corp bought a new position in IQVIA in the third quarter valued at approximately $28,000. Itau Unibanco Holding S.A. acquired a new position in shares of IQVIA in the second quarter valued at approximately $29,000. Finally, Rise Advisors LLC bought a new stake in shares of IQVIA during the first quarter worth $31,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Up 0.6 %

Shares of NYSE:IQV opened at $230.24 on Friday. The company has a market capitalization of $41.97 billion, a P/E ratio of 29.90, a P/E/G ratio of 2.18 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. The business’s 50 day simple moving average is $239.78 and its 200 day simple moving average is $232.00. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. During the same quarter in the prior year, the business posted $2.22 earnings per share. IQVIA’s revenue was up 2.3% compared to the same quarter last year. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Robert W. Baird lifted their target price on IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a research report on Friday, September 20th. Evercore ISI reduced their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Argus raised IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Finally, Jefferies Financial Group downgraded IQVIA from a “buy” rating to a “hold” rating and cut their price objective for the company from $266.00 to $242.00 in a report on Wednesday, July 24th. Five equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $269.36.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.